fbpx

Blog Page

Uncategorized

gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD) – Yahoo Finance

nVNS reduces symptoms of PTSD by 31% in sham-controlled study
ROCKAWAY, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that its gammaCore™ nVNS device has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for the treatment of posttraumatic stress disorder (PTSD) after showing a reduction of symptoms of PTSD by 31% when compared to sham.

PTSD is a highly prevalent and disabling disorder with limited approved treatment options. According to the U.S. Department of Veterans Affairs National Center for PTSD, approximately 15 million adults in the U.S. experience PTSD each year. In the Military and Veterans Administration alone, PTSD is reported to affect between 10-20% of veterans who served in each Operations Iraqi Freedom (OIF) and Enduring Freedom (OEF), the Gulf War (Desert Storm), and the Vietnam War. More than half of all patients with PTSD report severely impaired quality of life in areas including mood, social and family relationships, leisure activities, sense of well-being and life satisfaction.
The Breakthrough Device Designation was supported, in part, by research from an Emory-Georgia Tech team led by J. Douglas Bremner, M.D., in the Departments of Psychiatry and Radiology at the Emory University School of Medicine, and Omer T. Inan, Ph.D., from the School of Electrical and Computer Engineering and the Coulter Department of Biomedical Engineering at the Georgia Institute of Technology in Atlanta, Georgia. Their research, built upon a strong mechanistic rationale and animal studies, shows nVNS blocks sympathetic and inflammatory responses to memories of traumatic events in patients with PTSD, modulates brain responses to traumatic memory, and reduces symptoms of PTSD by 31% when compared to a sham stimulation.
Dr. Douglas Bremner commented, “Current treatments for PTSD involving medication and psychotherapy have limitations due to limited efficacy, possible side effects, and the unwillingness of many PTSD patients to engage in therapies that involve reliving traumatic memories. gammaCore represents a new class of treatment separate from medication or psychotherapy that is safe, relatively free of side effects, and does not involve costly and invasive procedures for implantation, like previous VNS devices approved by the FDA for treatment of refractory depression.”
“We appreciate the thorough and timely review by the FDA of our Breakthrough Device Request for gammaCore for the treatment of PTSD,” commented Eric Liebler, Senior Vice President of Neurology at electroCore. “The ability of nVNS to target several of the underlying causes of PTSD such as autonomic dysfunction, stress and inflammation, safely and effectively supports its potential as a breakthrough treatment for PTSD.”
The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
The goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to critical medical devices by speeding up their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with the FDA’s mission to protect and promote public health.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.
For more information, visit www.electrocore.com.
About gammaCore™
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.
gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients, and paroxysmal hemicrania and hemicrania continua in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if they:
Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
Have a metallic device, such as a stent, bone plate, or bone screw, implanted at or near the neck
Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Safety and efficacy of gammaCore have not been evaluated in the following patients:
Adolescent patients with congenital cardiac issues
Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
Pediatric patients (less than 12 years)
Pregnant women
Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
The U.S. FDA has cleared the gammaCore Sapphire CV device under an emergency use authorization for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing an exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved pharmacologic therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, using noninvasive vagus nerve stimulation (nVNS) on either side of the patient's neck.
gammaCore Sapphire CV has been authorized only for the duration of the statement that circumstances exist that warrant authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbbb-3(b)(1), until the authorization is terminated or revoked.
More information can be found at:
Letter of authorization: https://www.fda.gov/media/139967/download
Fact sheet for healthcare workers: https://www.fda.gov/media/139968/download
Patient information sheet: https://www.fda.gov/media/139969/download
Instructions for use of gammaCore: https://www.fda.gov/media/139970/download
Please refer to the gammaCore Instructions for Use for all the important warnings and precautions before using or prescribing this product.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans (including with respect to enrollment in ongoing studies); its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the issuance of U.S. and international patents providing expanded IP coverage; the possibility of future business models and revenue streams from the company’s potential utilizing nVNS for Posttraumatic stress disorder (PTSD), the potential of nVNS generally and gammaCore in particular and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
or
Media Contact:
Jackie Dorsky
electroCore
908-313-6331
jackie.dorsky@electrocore.com

Here are four inventions to watch
Online trading platform Robinhood Markets Inc said on Wednesday it plans to move a majority of its 3,400 employees to remote work permanently, joining a slew of top tech firms embracing a hybrid culture. The California-based company's move to adopt a 'remote first' approach, the plans for which were first shared with employees in December, will help create an accessible workplace, it said in a statement. "Being able to go primarily remote really means that now we can recruit and attract talent from almost anywhere," said Cynthia Owyoung, vice president of equity, inclusion and belonging at Robinhood.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.
Companies like Intellia Therapeutics and Editas Medicine are saying that this year will bring exciting developments.
Biogen stock tumbled late Tuesday after U.S. regulators limited which patients can access the controversial Alzheimer's treatment, Aduhelm.
A proposal would mean that most Medicare beneficiaries won't have access to Biogen's Alzheimer's disease drug Aduhelm.
Allogene is pioneering off-the-shelf cell therapy using gene editing, so when the FDA placed a clinical hold on its clinical trials in the fall, it went to work to find answers for itself and the emerging field.
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2022.
Regulators have proposed limiting access to the class of Alzheimer's disease drugs that includes the company's therapy, Aduhelm.
The spread of the Omicron variant has sent federal authorities scrambling to clarify Covid safety guidance for the purposes of everyday life
The omicron coronavirus symptoms you should watch out for and how to know if you have the omicron variant.
The FDA amended the fact sheet for Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine to include a rare risk of immune thrombocytopenia. This condition can lead to easy or excessive bruising and bleeding. "Reports of adverse events following use of the Janssen COVID-19 vaccine under emergency use authorization suggest an increased risk of immune thrombocytopenia during the 42 days following vaccination," the regulator said in a letter to J&J's arm, Janssen Biotech Inc. The U.S. Centers for Disease
Medicare should only cover Biogen ‘s Aduhelm drug for certain recipients who are enrolled in qualifying clinical trials, officials at the organization that oversees the national health insurance program proposed Tuesday evening. Biogen stock was tumbling. If approved, the decision would restrict access to the first Alzheimer’s therapy approved in decades by the Food and Drug Administration.
Despite having a billion-dollar drug in its portfolio, the potential for backdoor entry into the marijuana market, and being consistently profitable for years, Jazz Pharmaceuticals (NASDAQ: JAZZ) was battered about the head by the stock market last year with its stock falling 22.8%, according to data provided by S&P Global Market Intelligence. The decline started during the summer when Jazz reported second-quarter earnings that showed sales of its top sleep disorder drug, Xylem, plunged 25% from the prior year. While that's because patients were being transitioned over to its next-generation drug, Xywav, combined sales were only 3% higher.
Veru (NASDAQ: VERU), an oncology-focused biotech, saw its share price leap by over 20% on Tuesday, crushing not only the top stock market indexes, but also many peers in its sector. The reason why was clear: The company received an important regulatory nod for one of its key pipeline projects. In a press release published on Monday, Veru announced that the Food and Drug Administration (FDA) has granted Fast Track designation for the phase 3 registration program of its enobosarm.
The U.S. purchased 10 million courses of Pfizer’s antiviral treatment in a $5 billion deal. Where are they?
Ocugen jumped into the race to develop a vaccine for COVID-19 by partnering up with Bharat Biotech, an India-based biotech company. Bharat Biotech ran a late-stage clinical trial for the vaccine in question, Covaxin, in India, and earned emergency use authorization (EUA) for it there.
Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing and to bring improved insights to patients with breast cancer globally
A new real-world study funded by the Department of Veterans Affairs (VA) showed that compared to those who received Pfizer Inc's (NYSE: PFE) COVID-19 vaccine, Moderna Inc (NASDAQ: MRNA) vaccine recipients had a significantly lower risk of SARS-CoV-2 infection and related hospitalizations. Lower risk was observed across all age groups, comorbidity-burden categories, and race. Authors of the study, published as a pre-print last week, noted differences between Moderna's mRNA-1273 vaccine and Pfizer
More than 1,000 health care workers in Arizona have made a simple request of their government: Help us out. Why won't Gov. Doug Ducey listen?

source

× How can I help you?